BioWorld

Aug. 11, 2006

ImClone Hurt By Plans To Remain Independent Entity

ImClone Systems Inc. watched its shares drop Thursday following news that the company is nixing its plans for a merger, partnership or outright sale in favor of continuing on alone. (BioWorld Today) Read More

FDA Rejection Of Sparlon Trickles Down To Provigil

Mouse Model May Help Better Quantify Gene Therapy Risks

After Phase III Hit With Strep Drug, Advancis Planning NDA

Neurochem Secures Funding Through $60M Credit Facility

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 17, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...

Gene replacement rescues autism-related phenotypes in mice

BioWorld Science

Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...